Literature DB >> 28924974

Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.

David Narbey1,2,3, Anoosha Habibi2,3,4, Philippe Chadebech1,2,3, Armand Mekontso-Dessap5,6,7, Mehdi Khellaf7,8, Jean-Daniel Lelièvre7,9, Bertrand Godeau5,10, Marc Michel7,10, Frédéric Galactéros2,3,4,7, Rachid Djoudi1, Pablo Bartolucci2,3,4,7, France Pirenne1,2,3,7.   

Abstract

Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication of transfusion in sickle cell disease (SCD). The frequency of DHTR is underestimated because its symptoms mimic those of vaso-occlusive crisis and antibodies (Abs) are often not detectable. No predictive factors for identifying patients likely to develop DHTR have yet been defined. We conducted a prospective single-center observational study over 30 months in adult sickle cell patients. We included 694 transfusion episodes (TEs) in 311 patients, divided into occasional TEs (OTEs: 360) and chronic transfusion program (CTEs: 334). During follow-up, 15 cases of DHTR were recorded, exclusively after OTEs. DHTR incidence was 4.2% per OTE (95% CI [2.6; 6.9]) and 6.8% per patient during the 30 months of the study (95% CI [4.2; 11.3]). We studied 11 additional DHTR cases, to construct a predictive score for DHTR. The DHTR mortality is high, 3 (11.5%) of the 26 DHTR patients died. The variables retained in the multivariate model were history of DHTR, number of units previously transfused and immunization status before transfusion. The resulting DHTR-predictive score had an area under the ROC curve of 0.850 [95% CI: 0.780-0.930], a negative-predictive value of 98.4% and a positive-predictive value of 50%. We report in our study population, for the first time, the incidence of DHTR, and, its occurrence exclusively in occasionally transfused patients. We also describe a simple score for predicting DHTR in patients undergoing occasional transfusion, to facilitate the management of blood transfusion in SCD patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28924974     DOI: 10.1002/ajh.24908

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  22 in total

Review 1.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease.

Authors:  Aline Floch; Alexandre Morel; Fabian Zanchetta-Balint; Catherine Cordonnier-Jourdin; Slimane Allali; Maximilien Grall; Ghislaine Ithier; Benjamin Carpentier; Sadaf Pakdaman; Jean-Claude Merle; Radjiv Goulabchand; Tackwa Khalifeh; Ana Berceanu; Cécile Helmer; Christelle Chantalat-Auger; Véronique Frémeaux-Bacchi; Marc Michel; Mariane de Montalembert; Armand Mekontso-Dessap; France Pirenne; Anoosha Habibi; Pablo Bartolucci
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

3.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

Review 4.  How to avoid the problem of erythrocyte alloimmunization in sickle cell disease.

Authors:  France Pirenne; Aline Floch; Anoosha Habibi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 5.  Management of hemolytic transfusion reactions.

Authors:  Jeanne E Hendrickson; Ross M Fasano
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Erythropoietic properties of human induced pluripotent stem cells-derived red blood cells in immunodeficient mice.

Authors:  Jiusheng Deng; Moira Lancelot; Ryan Jajosky; Qiaomei Deng; Kristin Deeb; Natia Saakadze; Yongxing Gao; David Jaye; Senquan Liu; Sean R Stowell; Linzhao Cheng; John D Roback
Journal:  Am J Hematol       Date:  2021-11-24       Impact factor: 10.047

Review 7.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

Review 8.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

9.  Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.

Authors:  Giovanna Cannas; Léa Dubreuil; Axel Fichez; Mathieu Gerfaud-Valentin; Anne-Lise Debard; Arnaud Hot
Journal:  Am J Case Rep       Date:  2021-05-13

10.  Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition.

Authors:  Savannah Mwesigwa; Joann M Moulds; Alice Chen; Jonathan Flanagan; Vivien A Sheehan; Alex George; Neil A Hanchard
Journal:  Transfusion       Date:  2017-12-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.